These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 31856618)

  • 1. Cost-effectiveness analysis of ramucirumab treatment for patients with hepatocellular carcinoma who progressed on sorafenib with α-fetoprotein concentrations of at least 400 ng/ml.
    Zheng H; Qin Z; Qiu X; Zhan M; Wen F; Xu T
    J Med Econ; 2020 Apr; 23(4):347-352. PubMed ID: 31856618
    [No Abstract]   [Full Text] [Related]  

  • 2. Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib for Patients With Unresectable or Metastatic Hepatocellular Carcinoma.
    Zhang X; Wang J; Shi J; Jia X; Dang S; Wang W
    JAMA Netw Open; 2021 Apr; 4(4):e214846. PubMed ID: 33825837
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Zhu AX; Kang YK; Yen CJ; Finn RS; Galle PR; Llovet JM; Assenat E; Brandi G; Pracht M; Lim HY; Rau KM; Motomura K; Ohno I; Merle P; Daniele B; Shin DB; Gerken G; Borg C; Hiriart JB; Okusaka T; Morimoto M; Hsu Y; Abada PB; Kudo M;
    Lancet Oncol; 2019 Feb; 20(2):282-296. PubMed ID: 30665869
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma.
    Su D; Wu B; Shi L
    JAMA Netw Open; 2021 Feb; 4(2):e210037. PubMed ID: 33625508
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of Pembrolizumab as a Second-Line Therapy for Hepatocellular Carcinoma.
    Chiang CL; Chan SK; Lee SF; Wong IO; Choi HC
    JAMA Netw Open; 2021 Jan; 4(1):e2033761. PubMed ID: 33464318
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness analysis of antiviral therapy in patients with advanced hepatitis B virus-related hepatocellular carcinoma treated with sorafenib.
    Zhang P; Yang Y; Wen F; Wheeler J; Fu P; Li Q
    J Gastroenterol Hepatol; 2016 Dec; 31(12):1978-1985. PubMed ID: 27118432
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ramucirumab after prior sorafenib in patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein: Japanese subgroup analysis of the REACH-2 trial.
    Kudo M; Okusaka T; Motomura K; Ohno I; Morimoto M; Seo S; Wada Y; Sato S; Yamashita T; Furukawa M; Aramaki T; Nadano S; Ohkawa K; Fujii H; Kudo T; Furuse J; Takai H; Homma G; Yoshikawa R; Zhu AX
    J Gastroenterol; 2020 Jun; 55(6):627-639. PubMed ID: 32107609
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of sorafenib versus best supportive care in advanced hepatocellular carcinoma in Egypt.
    Hamdy Elsisi G; Nada Y; Rashad N; Carapinha J
    J Med Econ; 2019 Feb; 22(2):163-168. PubMed ID: 30479174
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Atezolizumab and bevacizumab combination compared with sorafenib as the first-line systemic treatment for patients with unresectable hepatocellular carcinoma: A cost-effectiveness analysis in China and the United states.
    Wen F; Zheng H; Zhang P; Liao W; Zhou K; Li Q
    Liver Int; 2021 May; 41(5):1097-1104. PubMed ID: 33556230
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-Effectiveness Analysis of Hepatic Arterial Chemotherapy for Advanced Hepatocellular Carcinoma in China: A Comparative Analysis of HAIC-FO and Sorafenib.
    Gao J; Liu S; Li SJ; Wang R; Meng ZH; Kong XS
    Med Sci Monit; 2024 Jul; 30():e944526. PubMed ID: 39033318
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of Ramucirumab
    Maesaka K; Sakamori R; Yamada R; Tahata Y; Ohkawa K; Oshita M; Tamura S; Hagiwara H; Mita E; Yakushijin T; Inada M; Kodama T; Hikita H; Tatsumi T; Takehara T
    Anticancer Res; 2021 Apr; 41(4):2187-2192. PubMed ID: 33813432
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of sorafenib versus SBRT for unresectable advanced hepatocellular carcinoma.
    Leung HW; Liu CF; Chan AL
    Radiat Oncol; 2016 May; 11():69. PubMed ID: 27193904
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-Effectiveness of Sorafenib Monotherapy and Selected Combination Therapy with Sorafenib in Patients with Advanced Hepatocellular Carcinoma.
    Ho JC; Hsieh ML; Chuang PH; Hsieh VC
    Value Health Reg Issues; 2018 May; 15():120-126. PubMed ID: 29704658
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-Effectiveness of Cabozantinib in the Second-Line Treatment of Advanced Hepatocellular Carcinoma.
    Soto-Perez-de-Celis E; Aguiar PN; Cordón ML; Chavarri-Guerra Y; Lopes GL
    J Natl Compr Canc Netw; 2019 Jun; 17(6):669-675. PubMed ID: 31200357
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative Efficacy of Cabozantinib and Ramucirumab After Sorafenib for Patients with Hepatocellular Carcinoma and Alpha-fetoprotein ≥ 400 ng/mL: A Matching-Adjusted Indirect Comparison.
    Trojan J; Mollon P; Daniele B; Marteau F; Martín L; Li Y; Xu Q; Piscaglia F; Zaucha R; Sarker D; Lim HY; Venerito M
    Adv Ther; 2021 May; 38(5):2472-2490. PubMed ID: 33822328
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regorafenib treatment for patients with hepatocellular carcinoma who progressed on sorafenib-A cost-effectiveness analysis.
    Shlomai A; Leshno M; Goldstein DA
    PLoS One; 2018; 13(11):e0207132. PubMed ID: 30408106
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative cost-effectiveness of cabozantinib as second-line therapy for patients with advanced hepatocellular carcinoma in Germany and the United States.
    Sieg M; Hartmann M; Settmacher U; Arefian H
    BMC Gastroenterol; 2020 Apr; 20(1):120. PubMed ID: 32316925
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Economic evaluation of camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma in the United States and China.
    Wei J; Xu K; Lin Y; Liu Q; Zhou C; Zhang P; Ma R; Zhang M; Zhang L; Li X
    Int J Clin Pharm; 2024 Oct; 46(5):1189-1199. PubMed ID: 38814514
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ramucirumab in elderly patients with hepatocellular carcinoma and elevated alpha-fetoprotein after sorafenib in REACH and REACH-2.
    Kudo M; Galle PR; Llovet JM; Finn RS; Vogel A; Motomura K; Assenat E; Merle P; Brandi G; Daniele B; Okusaka T; Tomášek J; Borg C; Dadduzio V; Morimoto M; Pracht M; Jen MH; Drove Ubreva N; Widau RC; Shinozaki K; Yoshikawa R; Zhu AX
    Liver Int; 2020 Aug; 40(8):2008-2020. PubMed ID: 32279446
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-Effectiveness Analysis of Camrelizumab Plus Rivoceranib Versus Sorafenib as a First-Line Therapy for Unresectable Hepatocellular Carcinoma in the Chinese Health Care System.
    Lang W; Deng L; Huang B; Zhong D; Zhang G; Lu M; Ouyang M
    Clin Drug Investig; 2024 Mar; 44(3):149-162. PubMed ID: 38300386
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.